Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe and Asia. The aim of this trial is to compare basal bolus treatment with insulin aspart and insulin NPH to biphasic insulin aspart treatment on blood glucose control in type 2 diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting; Isophane insulin, beef; Isophane Insulin, Human

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Currently treated with human insulin or insulin analogues for at least 3 months, with or without combination with OADs

• HbA1c between 8.0-10.5%

• Body mass index (BMI) below 35.0 kg/m2

• Able and willing to perform self-monitoring of blood glucose

Exclusion Criteria:

• Total daily insulin dose of 1.80 IU/kg or more

• Known or suspected allergy to trial product or related products

• Pregnancy, breast-feeding, the intention to become pregnant or judged not to be using adequate contraceptive measures